Primary Eccrine Porocarcinoma of the Breast: A Case Report and Review of Literature
Table 1
General characteristics, EPC histopathological and immunohistochemical features, treatment modalities, and outcomes in terms of response or survival.
Age/sex
Site and largest dimension (mm)
Lymph node/distant metastasis
Histopathological and IHC features of EPC
Treatment received
Treatment outcome
First author and year
92/F
Right breast, 60 mm
+
n.a.
Surgery (mastectomy)
Palliative care, adjuvant therapy rejected
Bonito (2020)
74/F
Right breast, 45 mm (first recurrence)
—
Infiltrative subtype with squamous differentiation and lymphovascular invasion Negative postop margins IHC positive for p63, CK5, and EMA and negative for ER and PR
Surgery (WLE) followed by reexcision (WLE) and adjuvant RT (66 Gy)
Overall survival of 3.3 years; first recurrence 22.5 months after initial resection and patient died 17.5 months after reexcision and adjuvant RT
Morten (2018)
54/M
n.a.
+
Unknown subtype IHC positive for AE1/AE3 and CEA and negative for S-100 and CK5/6
Surgery (WLE) followed by chemotherapy (cisplatin, 5-fluorouracil, and docetaxel) and reexcision (WLE)
Local recurrence and metastasis 1 year postop; complete remission achieved after docetaxel chemotherapy
